ARTICLE | Company News
Cypress Bioscience, Exagen deal
October 18, 2010 7:00 AM UTC
Cypress will divest its diagnostic business, including all testing services, IP rights and equipment to molecular diagnostics company Exagen for $4 million up front in cash and up to $4 million in pot...